Intravenous UDCA Administration during Cancer Chemotherapy, Liver Failure and Oral Route not Available


Authors : Palmieri B., Vadala M.

Volume/Issue : Volume 5 - 2020, Issue 3 - March

Google Scholar : https://goo.gl/DF9R4u

Scribd : https://bit.ly/3dWPy7K

Abstract : ntroduction: The chemotherapy of solid primary tumors with or without liver metastasis, very often impairs liver function causing high level of transaminase, GGT, bilirubin, alkaline phosphatase, and low albumin level due to intrinsic toxicity. The concept to add UDCA during or after chemotherapy cycles whenever liver toxicity risk is reasonably high, or impending, or already stabilized with variable digestive symptoms and low life quality, is nowadays very appealing.

ntroduction: The chemotherapy of solid primary tumors with or without liver metastasis, very often impairs liver function causing high level of transaminase, GGT, bilirubin, alkaline phosphatase, and low albumin level due to intrinsic toxicity. The concept to add UDCA during or after chemotherapy cycles whenever liver toxicity risk is reasonably high, or impending, or already stabilized with variable digestive symptoms and low life quality, is nowadays very appealing.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe